About MEAJO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions to authors | Online submission | Subscribe | Advertise | Contact | Login 
Middle East African Journal of Ophthalmology Middle East African Journal of Ophthalmology
Users Online: 126   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
ORIGINAL ARTICLE
Year : 2021  |  Volume : 28  |  Issue : 1  |  Page : 18-22

Outcomes of combination therapy using aflibercept and dexamethasone intravitreal implant versus dexamethasone monotherapy for macular edema secondary to retinal vein occlusion


1 Faculty of Medicine and Medical Sciences, Holy Spirit University of Kaslik (USEK), Jounieh; Department of Ophthalmology, University Hospital Center – Notre Dame des Secours, Byblos; Department of Ophthalmology, Clinique du Levant; Faculty of Medicine, Lebanese University, Beirut, Lebanon
2 Faculty of Medicine and Medical Sciences, Holy Spirit University of Kaslik (USEK), Jounieh; Department of Dermatology, University Hospital Center – Notre Dame des Secours, Byblos, Lebanon
3 Department of Ophthalmology, Clinique du Levant; Faculty of Medicine, Lebanese University, Beirut; Holy Family University, Batroun, Lebanon

Correspondence Address:
Dr. Georges Harb
Department of Ophthalmology, Clinique du Levant, Beirut, Lebanon. Faculty of Medicine, Lebanese University, Beirut, Lebanon. Holy Family University, Batroun
Lebanon
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/meajo.MEAJO_297_19

Rights and Permissions

PURPOSE: The purpose of this study was to evaluate the efficacy of the combination therapy of intravitreal aflibercept 2 mg (Eylea®) and a sustained-release dexamethasone 0.7 mg intravitreal implant (Ozurdex®) versus dexamethasone alone in providing better visual acuity in eyes with macular edema (ME) secondary to retinal vein occlusion (RVO). METHODS: Seventy-four eyes of 74 patients with treatment-naïve ME secondary to RVO were included in this prospective nonrandomized case series and were studied over a 12-month follow-up period. Patients in the dexamethasone monotherapy group were treated with an initial Ozurdex® injection while patients in the combination therapy group were treated with an Eylea® injection followed 2 weeks later by an Ozurdex® injection. The treatment was repeated as needed. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure were evaluated periodically. The primary outcome measure was the BCVA. The secondary outcome measures included CMT, number of retreatments, and safety parameters. RESULTS: At 1 year, the primary endpoint was met. Patients receiving combined therapy had better mean visual acuity changes from baseline compared to those receiving monotherapy (0.369 ± 0.221 logarithm of the minimum angle of resolution [logMAR] vs. 0.218 ± 0.171 logMAR; P = 0.002). The secondary endpoints were not met since there were no significant differences in mean reductions in CMT (272.67 ± 82.35 vs. 248.11 ± 159.73; P = 0.412) and the mean number of retreatments was similar in the two groups (1.75 ± 1.13 vs. 1.42 ± 0.64; P = 0.126). CONCLUSION: Aflibercept with dexamethasone implants achieved better visual outcomes compared to dexamethasone monotherapy with no significant differences in intravitreal retreatment rates at the 1st year in eyes with ME secondary to RVO.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1106    
    Printed92    
    Emailed0    
    PDF Downloaded86    
    Comments [Add]    

Recommend this journal